Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non-ST-elevation acute coronary syndrome

Circulation

Volumn 116, Issue 14, 2007, Pages 1540-1548

  Wollert, Kai C ^a   Kempf, Tibor ^a   Lagerqvist, Bo ^b   Lindahl, Bertil ^b   Olofsson, Sylvia ^b   Allhoff, Tim ^a   Peter, Timo ^a   Siegbahn, Agneta ^b   Venge, Per ^b   Drexler, Helmut ^a   Wallentin, Lars ^b,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

Coronary disease; Growth differentiation factor 15; Myocardial infarction; Revascularization; Risk factors; Treatment outcome

Indexed keywords

CYTOKINE; DALTEPARIN; GROWTH DIFFERENTIATION FACTOR 15; PLACEBO; TROPONIN T; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY RISK; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; CYTOKINES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; RISK FACTORS; TREATMENT OUTCOME; TROPONIN T;

EID: 34848820630     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.697714     Document Type: Article

References (23)

1. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE II, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction.) Circulation. 2007;116:e148-e304.
2. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002;23:1809-1840.
3. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999;354:708-715.
4. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
5. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH, Hille DA, DeLucca PT, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001;286:2405-2412.
6. Diderholm E, Andren B, Frostfeldt G, Genberg M, Jernberg T, Lagerqvist B, Lindahl B, Venge P, Wallentin L. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. Am Heart J. 2002;143:760-767.
7. Holmvang L, Clemmensen P, Lindahl B, Lagerqvist B, Venge P, Wagner G, Wallentin L, Grande P. Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment. J Am Coll Cardiol. 2003;41:905-915.
8. Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, Widimsky P, McCullough PA, Hunt D, Braunwald E, Yusuf S. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005;293:2908-2917.
9. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006;98:351-360.
10. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L. Prognostic value of growth-differentiation factor-15 in patients with non-ST-segment elevation acute coronary syndrome. Circulation. 2007;115:962-971.
11. Lagerqvist B, Husted S, Kontny F, Naslund U, Stahle E, Swahn E, Wallentin L. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol. 2002;40:1902-1914.
12. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001;286:2107-2113.
13. Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, Stridsberg M, Venge P, Wallentin L. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol. 2003;42:1909-1916.
14. Lindahl B, Lindback J, Jernberg T, Johnston N, Stridsberg M, Venge P, Wallentin L. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a FRagmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol. 2005;45:533-541.
15. Lagerqvist B, Diderholm E, Lindahl B, Husted S, Kontny F, Stahle E, Swahn E, Venge P, Siegbahn A, Wallentin L. FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease. Heart. 2005;91:1047-1052.
16. Johnston N, Jernberg T, Lagerqvist B, Wallentin L. Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease. Am Heart J. 2006;152:1052-1058.
17. Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T, Klein G, Drexler H, Johnston N, Wallentin L, Wollert KC. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem. 2007;53:284-291.
18. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
19. Jernberg T, James S, Lindahl B, Johnston N, Stridsberg M, Venge P, Wallentin L. Natriuretic peptides in unstable coronary artery disease. Eur Heart J. 2004;25:1486-1493.
20. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, Wheatley DJ, Pocock SJ. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet. 2002;360:743-751.
21. de Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, Bendermacher PE, Michels HR, Sanders GT, Tijssen JG, Verheugt FW. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. 2005;353:1095-1104.
22. Wollert KC. Growth-differentiation factor-15 in cardiovascular disease: from bench to bedside, and back. Basic Res Cardiol 2007; June 5. Epub ahead of print.
23. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal. 2006;8:1907-1939.